IOVANCE BIOTHERAPEUTICS, INC. Payments to Acquire Available-for-sale Securities
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Payments to Acquire Available-for-sale Securities of $534.72 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-08-06
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2020-06-30 was $521.79M, a 366.12% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2020-03-31 was $12.92M, a 85.51% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2019-12-31 was $63.78M, a 74.19% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2019-09-30 was $152.75M, a 2.58% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2019 was $417.66M, a 1.98% decline from fiscal 2018.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2018 was $426.08M.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- IOVANCE BIOTHERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $110.25M, a 21.62% decline from fiscal 2015.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 6 month as first filed | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|---|
| 2020-06-30 | $521.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $534.72M 10-Q · filed 2020-08-06 | $598.50M derived: sum of 3 quarters · filed 2020-08-06 | $751.25M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2020-03-31 | $12.92M 10-Q · filed 2020-05-05 | $76.70M derived: sum of 2 quarters · filed 2020-05-05 | $229.45M derived: sum of 3 quarters · filed 2020-05-05 | $341.40M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-12-31 | $63.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $216.53M derived: sum of 2 quarters · filed 2020-02-25 | $328.47M derived: sum of 3 quarters · filed 2020-08-06 | $417.66M 10-K · filed 2020-02-25 | |
| 2019-09-30 | $152.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $264.69M derived: sum of 2 quarters · filed 2020-08-06 | $353.88M 10-Q · filed 2019-11-04 | $600.97M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-06-30 | $111.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $201.13M 10-Q · filed 2020-08-06 | $448.22M derived: sum of 3 quarters · filed 2020-08-06 | $597.13M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $89.19M 10-Q · filed 2020-05-05 | $336.27M derived: sum of 2 quarters · filed 2020-05-05 | $485.18M derived: sum of 3 quarters · filed 2020-05-05 | $515.27M derived: sum of 4 quarters · filed 2020-05-05 | |
| 2018-12-31 | $247.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $396.00M derived: sum of 2 quarters · filed 2020-02-25 | $426.08M derived: sum of 3 quarters · filed 2020-02-25 | $426.08M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $148.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $178.99M derived: sum of 2 quarters · filed 2019-11-04 | $178.99M 10-Q · filed 2019-11-04 | $178.99M derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | $30.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $30.08M 10-Q · filed 2019-08-01 | $30.08M derived: sum of 3 quarters · filed 2019-08-01 | $30.08M derived: sum of 4 quarters · filed 2019-08-01 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2019-05-07 | $0.00 derived: sum of 3 quarters · filed 2019-05-07 | $0.00 derived: sum of 4 quarters · filed 2019-05-07 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $41.91M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-03 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $41.91M derived: sum of 3 quarters · filed 2019-02-28 | $80.98M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $41.91M derived: sum of 2 quarters · filed 2019-02-28 | $80.98M derived: sum of 3 quarters · filed 2019-02-28 | $110.25M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $41.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $80.98M derived: sum of 2 quarters · filed 2017-11-02 | $110.25M 10-Q · filed 2017-11-02 | $155.68M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-06-30 | $39.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $68.34M 10-Q · filed 2017-08-03 | $113.77M derived: sum of 3 quarters · filed 2018-03-12 | $112.72M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-03-31 | $29.27M 10-Q · filed 2017-05-03 | $74.70M derived: sum of 2 quarters · filed 2018-03-12 | $73.66M derived: sum of 3 quarters · filed 2018-03-12 | $169.94M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2015-12-31 | $45.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $44.38M derived: sum of 2 quarters · filed 2018-03-12 | $140.66M derived: sum of 3 quarters · filed 2018-03-12 | $140.66M 10-K · filed 2018-03-12 | |
| 2015-09-30 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $95.24M derived: sum of 2 quarters · filed 2016-11-04 | $95.24M 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | $96.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $96.28M 10-Q · filed 2016-08-09 | $96.28M 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-09 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-09 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |